AlphaYou
Overview
Smart money at a glance
Filings to Oct 7, 2026Net selling: insiders sold $67M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$67M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 6 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 9 awardsAwards on record
Market overview
Fundamentals Oct 7- Open
- $57.31
- 52-wk high
- $68.73
- High
- $58.60
- 52-wk low
- $22.59
- Low
- $55.86
- Prev close
- $56.93
- Mkt cap
- $5.36B
- Volume
- 2.09M
- Fwd P/E
- 39.8x
- Beta
- 1.14
- P/S
- 9.2x
- P/B
- 229.9x
- Profit margin
- -7.3%
- Op margin
- +2.3%
- ROE
- -236.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TVTX filings
Are insiders buying or selling Travere Therapeutics Inc (TVTX) stock?
Net selling: insiders sold $67M and bought $0 of TVTX stock on the open market in the 90 days to Oct 7, 2026, according to SEC Form 4 filings. $67M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Dube, Eric M (Chief Executive Officer), who sold $25.4M. The latest filing was on Sep 18, 2026.
Which members of Congress have traded TVTX recently?
None. No member of Congress disclosed a TVTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TVTX smart-money data?
This summary uses filings available on Oct 7, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- QR
Qube Research
$62.1M
added
- DS
D.E. Shaw
$57.0M
added
- BO
Bank of America
$219.6M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in TVTX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.23 a share below what analysts expected.
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.14 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$0.37 / -$0.14Alpha Vantage | -$0.23 miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 4, 2026 | $0.05 / -$0.06Alpha Vantage | +$0.11 beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 19, 2026 | $0.37 / -$0.04Alpha Vantage | +$0.41 beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $0.59 / -$0.08Alpha Vantage | +$0.67 beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $0.13 / $0.04Alpha Vantage | +$0.09 beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | -$0.19 / -$0.39Alpha Vantage | +51.28% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 20, 2025 | -$0.47 / -$0.38Alpha Vantage | -24.14% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | -$0.46 / -$0.54Alpha Vantage | +14.81% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Oct 29, 2026, in 22 days
Estimates as of Oct 3, 2026
EPS expected
-$0.57 to $1.16
Revenue expected
14 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $164.9M | $129.7M | $127.2M | $169.6M |
| Cost of what it sold | $1.6M | $2.6M | $26.8M | $2.2M |
| Gross profit | $163.3M | $127.1M | $100.4M | $167.4M |
| What it spent | ||||
| Research and development | $51.9M | $57.9M | $57.1M | $60.3M |
| Sales and admin | $86.5M | $101.7M | $80.3M | $96.1M |
| Other operating costs | — | — | — | $7.1M |
| Total operating expenses | $138.3M | $159.6M | $137.3M | $163.5M |
| What was left | ||||
| Operating profit | $24.9M | -$32.4M | -$36.9M | $4.0M |
| Interest on debt | $2.8M | $2.3M | $2.3M | $2.1M |
| Profit before tax | $25.7M | -$21.1M | -$36.7M | -$35.0M |
| Tax | $8.0K | $921.0K | -$120.0K | -$204.0K |
| Net profit | $25.7M | $2.7M | -$37.1M | -$34.8M |
| EBITDA | $44.3M | -$632.0K | -$9.2M | -$32.9M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
How (TVTX) Movements Inform Risk Allocation Models
Leans bearishOct 4Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history
Leans bullishOct 3Travere Therapeutics (TVTX) to Present New FILSPARI Data at ASN Kidney Week 2026
NeutralOct 2Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders
BearishOct 1Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
BearishSep 30Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
BullishSep 30Travere Therapeutics Inc. (TVTX) Key Financial Ratios – Valuation, Profitability & More
NeutralSep 30RTRX5376243 Bond Profile: Coupon and Redemption
NeutralSep 26